INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

Core Viewpoint - A class action lawsuit has been filed against Replimune Group, Inc. concerning allegations of securities fraud and unlawful business practices related to the company's recent FDA response regarding its drug application [1][2]. Group 1: Lawsuit Details - The class action lawsuit is focused on whether Replimune and certain officers or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until September 22, 2025, to request to be appointed as Lead Plaintiff if they purchased Replimune securities during the Class Period [2]. Group 2: FDA Response and Stock Impact - On July 22, 2025, Replimune received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for RP1 in combination with nivolumab for advanced melanoma [4]. - The CRL indicated that the FDA could not approve the application in its current form, citing inadequacies in the IGNYTE trial and issues with the patient population's heterogeneity [4]. - Following the announcement, Replimune's stock price fell by $9.52 per share, or 77.24%, closing at $2.81 per share on the same day [4].